Adagio Medical’s FULCRUM-VT Study Results to Debut at HRS 2026
Event summary
- Adagio Medical’s FULCRUM-VT study results accepted for late-breaking session at Heart Rhythm Society 2026.
- Study is first IDE-powered evaluation of Ultra-Low Temperature Ablation (ULTA) for scar-related ventricular tachycardia (VT).
- Presentation scheduled for April 26, 2026, with Dr. Atul Verma as lead presenter.
- Results aim to support FDA premarket approval (PMA) for Adagio’s vCLAS™ Cryoablation System.
- Investor event scheduled for April 27, 2026, featuring key study investigators.
The big picture
Adagio Medical’s FULCRUM-VT study represents a critical milestone in the advancement of catheter ablation technologies for ventricular tachycardia. The results could position Adagio as a leader in the treatment of scar-related VT, a growing concern among patients with structural heart disease. Success in this study would not only expand Adagio’s market reach but also set a new benchmark for endocardial ablation techniques.
What we're watching
- Regulatory Pathway
- Whether the FULCRUM-VT results will meet FDA standards for premarket approval.
- Market Expansion
- The pace at which Adagio can commercialize ULTA technology in the U.S. following potential approval.
- Competitive Positioning
- How Adagio’s ULTA technology differentiates against existing VT ablation treatments.
Related topics